Myeloproliferative Disorders

1. Chronic myelogenous leukemia (CML)
2. Polycithemia vera (PV)
3. Essential thrombocytemia (ET)
4. Idiopathic myelofibrosis (previously called agnogenic myeloid metaplasia (AMM)

Non Hodgkin's Lymphoma International Prognostic Index

Five Adverse Prognostic Factors

1. Age greater than 60 years
2. Ann Arbor Stage III/IV
3. More than one extranodal site
4. Serum LDH concentration > normal
5. ECOG performance status

Prognostic Index By Risk Group










Age Adjusted Prognostic Index (less or equal 60 years old)

For this adjustment, age and number of extranodal sites are not used










NEJM 1993:329;987-994

Complications After HSCT

Early (0-30 Days)
A.Regimen related toxicity
1.Mucositis (65-70%)
2.Myocarditis & Pericarditis from either cyclophosphamide or TBI (rare)
3.Hemorrhagic Cystitis (10%)
4.Veno-occlusive disease (5-40%)
5.Pneumonitis (10- 20%)
6.Alveolar hemorrhage (5-10%)
B.Infections (75%)
C.Graft Failure (2-10%)
D.Adverse drug reactions from Polypharmacy (Common)

Intermediate (1-3 months)
Acute GVHD (20-50%) (more frequent with non-sibling donors)

Late (Beyond 3 months)
A.Chronic GVHD (20 – 40%)
B.Hypothyroidism (30 – 50%)
C.Growth disturbances in children (common)
D.Sterility/Hypogonadysm (common)
E.Cataracts (25 – 40%)
F.Avascular necrosis of bone and demineralization of bone (5 – 15%)
G.Malignant relapse (Variable)
H.Second Malignancy (2-10%)